Fenebrutinib, a Bruton's tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways
Summary
Our study enhances the understanding of BTK functions in human microglial signaling that are relevant to MS pathogenesis and suggests that fenebrutinib could attenuate detrimental microglial activity associated with FcγR activation in people with MS. © 2024. The Author(s).
| Authors | Langlois J, Lange S, Ebeling M, Macnair W, Schmucki R, Li C, DeGeer J, Sudharshan TJJ, Yong VW, Shen YA, Harp C, Collin L, Keaney J |
|---|---|
| Journal | Journal of neuroinflammation |
| Publication Date | 2024 Oct 27;21(1):276 |
| PubMed | 39465429 |
| PubMed Central | PMC11514909 |
| DOI | 10.1186/s12974-024-03267-5 |